BACKGROUND: Infarcted myocardium can remodel after successful reperfusion, resulting in left ventricular dilation and heart failure. Epicardial infarct repair (EIR) using a bioinductive extracellular matrix (ECM) biomaterial is a novel surgical approach to promote endogenous myocardial repair and functional recovery after myocardial infarction. Using a pre-clinical porcine model of coronary ischemia-reperfusion, we assessed the effects of EIR on regional functional recovery, safety, and possible mechanisms of benefit. METHODS: An ECM biomaterial (CorMatrix ECM) was applied to the epicardium after 75 minutes of coronary ischemia in a porcine model. Following ischemia-reperfusion injury, animals were randomly assigned in 2:1 fashion to EIR (n ¼ 8) or sham treatment (n ¼ 4). Serial cardiac magnetic resonance imaging was performed on normal (n ¼ 4) and study animals at baseline (1 week) and 6 weeks after treatment. Myocardial function and tissue characteristics were assessed. RESULTS: Functional myocardial recovery was significantly increased by EIR compared with sham treatment (change in regional myocardial contraction at 6 weeks, 28.6 Ϯ 14.0% vs 4.2 Ϯ 13.5% wall thickening, p o 0.05). Animals receiving EIR had reduced adhesions compared with animals receiving sham treatment (1.44 Ϯ 0.51 vs 3.08 Ϯ 0.89, p o 0.05). Myocardial fibrosis was not increased, and EIR did not cause myocardial constriction, as left ventricular compliance by passive pressure distention at matched volumes was similar between groups (13.9 Ϯ 4.0 mm Hg in EIR group vs 16.0 Ϯ 5.2 mm Hg in sham group, p ¼ 0.61). Animals receiving EIR showed evidence of vasculogenesis in the region of functional recovery. CONCLUSIONS: In addition to the beneficial effects of successful reperfusion, EIR using a bioinductive ECM enhances myocardial repair and functional recovery. Clinical translation of EIR early after myocardial infarction as an adjunct to surgical revascularization may be warranted in the future.
artery bypass grafting (CABG) is sometimes performed early after MI, but complete revascularization is not always achieved, and CABG does not directly target the infarcted myocardium. Myocardial remodeling can result in interstitial fibrosis, progressive ventricular dilation, and subsequent heart failure. "Biosurgical" strategies applied at the time of surgical revascularization specifically to target the infarcted myocardium may help promote healing, prevent heart failure, and improve outcomes for patients with preexisting ischemic injury.
The extracellular matrix (ECM) influences cardiac remodeling and function after MI. Healthy ECM provides structural support to tissues and regulates cardiac cell morphology, differentiation, migration, and proliferation, 2 which act in concert to impact tissue function. After tissue injury, ECM is essential for endogenous repair and may mediate the potential for cellular regeneration. 3, 4 The application of a biologic ECM construct with bioinductive properties from retained growth factors, cytokines, and matricellular proteins, such as porcine small intestine submucosa extracellular matrix (SIS-ECM), may enhance endogenous tissue repair. SIS-ECM is a decellularized ECM construct that retains its native three-dimensional architecture and cell signaling proteins, providing a homeostatic environment to promote cell function and survival. [5] [6] [7] CorMatrix ECM (CorMatrix Cardiovascular, Inc., Roswell, GA) is a commercially available SIS-ECM that is approved by the US Food and Drug Administration and has been used previously in cardiac surgery applications. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We established proof-of-concept for epicardial infarct repair (EIR) with SIS-ECM in a rodent model demonstrating that local application of SIS-ECM biomaterial to the epicardial surface of infarcted myocardium limits structural remodeling after MI and improves myocardial function. 8 The epicardium itself is a key player in repair after MI. Following ischemia, endogenous cells within the epicardium become activated, resulting in epicardial thickening. 18 This process mobilizes key progenitor cell niches located within the epicardial space by epithelial mesenchymal transition (EMT). [19] [20] [21] [22] Epicardial progenitor cells differentiate into (myo)fibroblasts, vascular smooth muscle cells, or cardiac myocytes. 19, 20, 22 Restoring local homeostatic queues by application of a healthy biologic ECM construct containing angiogenic growth factors may enhance differentiation toward a vascular phenotype, promoting endogenous healing pathways beneficial in the setting of ischemia.
In this study, we examined the influence of EIR using SIS-ECM on regional myocardial recovery as an adjunct to successful reperfusion after MI. We assessed procedural safety, efficacy on regional functional recovery, and possible mechanisms of post-MI repair for EIR.
Methods

Experimental animals
All animal experiments were performed in accordance with the Canadian Council on Animal Care Guide for the Care and Use of Experimental Animals and the National Society for Medical Research Guide for the Care and Use of Laboratory Animals and approved by the University of Calgary Animal Care Committee. Male Landrace pigs weighing 25 kg were obtained from Neufeld Farms (Alberta, Canada).
Ischemia-reperfusion model and EIR procedure
The ischemia-reperfusion model was adapted from the Gorman Cardiovascular Research Group sheep model. 23 Animals were intubated and mechanically ventilated with medical-grade oxygen and 2% to 3% isoflurane and administered continuous infusions of lactated Ringer's solution (0.04 ml/kg/min) and lidocaine (0.04 mg/kg/min). After median sternotomy, diagonal branches of the left anterior descending coronary artery were ligated for 75 minutes and then reperfused. Animals were then randomly assigned 2:1 to receive EIR or a sham procedure. Animals receiving EIR received SIS-ECM (CorMatrix-ECM) secured to the epicardial surface of the heart overlying the infarct territory using a running 5-0 polypropylene (Prolene) suture. Animals receiving sham treatment received a running 5-0 Prolene suture encompassing the infarct border without securing SIS-ECM.
Cardiac magnetic resonance image acquisition
Serial cardiac magnetic resonance (CMR) imaging was performed at baseline (1 week) and 6 weeks after treatment. Animals were mechanically ventilated, and anesthesia consisting of inhaled isoflurane (r1.0%) and nitrous oxide (r1.0%) and a continuous intravenous infusion of ketamine (0.3 mg/ml), fentanyl (0.04 mg/ml), and midazolam (0.025 mg/ml) at a rate of 30 to 100 ml/hour was maintained to achieve a mean arterial pressure 460 mm Hg. CMR imaging was performed using a 1.5-tesla magnetic resonance imaging scanner (Avanto; Siemens Healthcare GmbH; Erlangen, Germany) at the Stephenson Cardiac MR Center (Calgary, Alberta, Canada). Images were acquired using cine imaging, late gadolinium enhancement (LGE), and T1-mapping by saturation recovery single-shot acquisition 24 protocols.
CMR image analysis
CMR images were analyzed by readers blinded to treatment group using cvi 42 software (Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada). The left ventricle was divided into a 3 Â 24-segment model, and infarcted myocardium was defined as all segments with 450% LGE at a threshold of 45 SD above the mean. The peri-infarct zone was defined as all segments immediately adjacent to any infarcted segment. All remaining segments were defined as remote to the infarct territory. Regional myocardial function was measured as an average of the percent wall thickening of all segments within a defined territory. Myocardial fibrosis was quantified by measuring the mean extracellular volume (ECV) within a defined territory calculated from regional pre-contrast and post-contrast T1 values. Mean peak systolic strains stratified by territory were measured using a custombuilt multi-axial adaptation of the algorithm described by Satriano et al. 26 A clinical cardiologist (J.A.W.) with expertise in CMR imaging blinded to treatment group reviewed all analyses.
An anterolateral thoracotomy was performed, and the dissection of intrathoracic adhesions between the posterior sternal surface and the pericardium ( Figure 1A ) was evaluated by 3 independent observers, blinded to the treatment group, using an adapted semiquantitative scale (Table 1) . 27, 28 Adhesion tenacity was graded according to the extent of blunt vs sharp dissection required. Hearts were explanted and sectioned in short axis. Transmural biopsy specimens of the infarct, peri-infarct, and remote myocardial territories were taken.
Histology
Myocardial biopsy specimens were fixed in 10% Neutral Buffered Formalin (VWR International, Inc., West Chester, PA), embedded in paraffin, and stained with Masson's trichrome. Vascular densities were quantified by averaging the number of vascular structures per high-power field in 3 randomly captured images of the infarcted myocardium per animal. Images were reviewed and interpretations confirmed by a clinical pathologist blinded to treatment group. 
Statistical analysis
All data summaries are expressed as mean Ϯ SD. GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA) statistical software was used for all statistical analyses. The 2 groups were compared using the 2-sample t-test with unequal variances. Statistical significance was declared at 2-sided 5% α level. No adjustments for multiple testing were made. All statistical analyses were reviewed and confirmed by a biostatistician.
Results
Study animals
There were 12 animals randomly assigned to either sham (n ¼ 4) or EIR (n ¼ 8) groups. Animals were monitored daily for signs of heart failure, respiratory complications, infection, and sudden death, none of which were observed in either group.
Intrathoracic adhesions
Intrathoracic adhesions were assessed post-mortem in all animals to evaluate the impact of the implanted biomaterial on mediastinal fibrosis. Adhesion tenacity above that equivalent to a "virgin chest" was observed in all postoperative animals; however, in animals that received EIR, the tissue planes were more clearly defined and easily dissected, reflected by a lower adhesion tenacity score compared with animals that received sham treatment (1.3 Ϯ 0.4 vs 2.8 Ϯ 0.9, p ¼ 0.003) ( Figure 1B ). Post-mortem examination revealed good integration of the SIS-ECM biomaterial without evidence of encapsulation. Integration with host myocardium was confirmed by histology, which demonstrated ingrowth of the epicardium into the SIS-ECM ( Figure 1C ) and infiltration of cells as well as the development of granulation tissue and vascular structures within the SIS-ECM ( Figure 1C and D) .
Interstitial myocardial fibrosis
ECV was assessed by CMR as a measure of myocardial fibrosis. Baseline CMR revealed an increase in ECV in infarcted vs normal animals (0.31 Ϯ 0.02 g/ml vs 0.24 Ϯ 0.01 g/ml, p ¼ 0.003). Despite the addition of exogenous ECM in the animals receiving EIR, ECV within the infarcted territory was comparable in EIR-treated and sham-treated animals at baseline (0.53 Ϯ 0.09 g/ml vs 0.52 Ϯ 0.03 g/ml, p ¼ 0.86) ( Figure 1E ). Although ECV decreased within all territories (infarct, peri-infarct, and remote myocardium) from baseline to 6 weeks, no difference was observed between EIR-treated and shamtreated animals ( Figure 1E and F) , indicating that the SIS-ECM biomaterial did not precipitate myocardial fibrosis. (Figure 2A ), suggesting that SIS-ECM biomaterial applied to the epicardium does not adversely alter LV compliance and therefore should not impair LV filling.
Myocardial strain
Regional myocardial restraint was also assessed at the epicardial surface underlying the SIS-ECM biomaterial by measuring myocardial strain using CMR. At baseline, shamtreated animals demonstrate a positive strain (0.71 Ϯ 1.36%) indicating dyskinesis in the infarcted myocardium, whereas EIR-treated animals demonstrate a neutral strain (À0.09 Ϯ 2.04%), suggesting SIS-ECM may limit dyskinesis of the infarcted myocardium. By 6 weeks, strain in sham-treated animals became more positive (1.56 Ϯ 2.03%, p ¼ 0.58), consistent with worsening dyskinesis. However, in EIR-treated animals, strain became increasingly negative from baseline to 6 weeks (À0.09 Ϯ 2.04% vs À2.29 Ϯ 1.30%, p ¼ 0.049) ( Figure 2B ), consistent with improved myocardial contraction suggestive of functional recovery.
Regional myocardial recovery
Measures of global LV function (Table 2) were similar between groups; however, significant regional changes within the infarcted myocardium were observed. Wall thickening measured by CMR demonstrated severe hypokinesis within the infarcted myocardium of EIR-treated and sham-treated animals at baseline (6.1 Ϯ 7.9% vs 5.7 Ϯ 6.7%, p ¼ 0.93) ( Figure 2C) . A clinically significant increase in wall thickening demonstrating functional recovery was observed in EIR-treated animals compared with sham-treated animals by 6 weeks (28.6 Ϯ 14.0% vs 4.2 Ϯ 13.5%, p ¼ 0.021) (Figure 2C and D) . This functional improvement is observed in myocardial segments identified by CMR as non-viable despite successful revascularization, illustrating efficacy of therapy beyond the benefits of complete reperfusion. An improvement in wall thickening in the peri-infarct territory was also observed from baseline to 6 weeks after treatment in EIR-treated and sham-treated animals (18.0 Ϯ 10.1% vs 14.1 Ϯ 13.0%, p ¼ 0.58); however, no significant difference in the magnitude of myocardial recovery was observed between groups ( Figure 2E and F), suggesting that EIR had minimal influence beyond the effects of reperfusion on functional recovery within the border zone surrounding the infarct; myocardium likely to recover with successful reperfusion alone.
Infarct volume
Infarct volume was measured as a percent of the left ventricle by LGE on CMR. Infarct volume measured at baseline was not significantly different between EIR-treated and sham-treated animals (13.40 Ϯ 3.85% vs 13.01 Ϯ 5.61%, p ¼ 0.89), indicating that the functional recovery observed in EIR-treated animals was not due to a smaller baseline infarct size. Infarct volume did not change significantly between baseline and 6 weeks in either EIRtreated or sham-treated animals ( Figure 2G and H) , suggesting the mechanism responsible for the functional recovery observed is not related to decreased infarct size.
Vasculogenesis and epicardial activation
Histologic examination of the explanted LV myocardium demonstrated regions of intact cardiomyocytes within the infarct ( Figure 3A and B). Surrounding these regions was a marked increase in vascularity in EIR-treated animals vs sham animals (18.6 Ϯ 5.6 vessels vs 4.8 Ϯ 3.6 vessels per highpower field, p ¼ 0.004) (Figure 3A-D ). An increased density of small capillary vessels and small arteriolar vessels containing vascular smooth muscle cells was observed in EIR-treated animals vs sham-treated animals (9.8 Ϯ 4.1 capillary vessels vs 3.8 Ϯ 3.0 capillary vessels per high-power field, p ¼ 0.043; 8.8 Ϯ 1.9 arterioles vs 1.0 Ϯ 0.8 arterioles per high-power field, p o 0.0001) ( Figure 3E and F) , suggesting EIR promotes vasculogenesis and may restore microvascular blood flow to these intact cardiomyocytes resulting in recovery of function in these otherwise likely hibernating cells.
Further histologic examination of the myocardium demonstrated an increase in vascularity within the epicardium underlying the SIS-ECM biomaterial ( Figure 3C ) and thickening of the epicardial surface in EIR-treated animals. Although the epicardial surface did appear activated in the sham-treated animals, the extent of epicardial thickening in the EIR-treated animals was significantly higher (3.8-Ϯ 2.2-fold vs 7.9-Ϯ 3.2-fold above normal; p o 0.0001) (Figure 4) , suggesting that the increase in vascularity observed in EIR-treated animals may be the result of enhanced activation of the epicardium, perhaps involving EMT.
Discussion
ECM has been identified as a key player in myocardial healing after ischemic injury and an essential mediator for endogenous tissue repair and cell regeneration. 3, 4, 11 A biosurgical approach applying a healthy ECM construct, such as SIS-ECM, to the epicardial space after ischemic injury may promote endogenous repair. SIS-ECM is an ideal biomaterial for EIR given its commercial availability (approved by the US Food and Drug Administration for cardiac repair), biocompatibility, and established safety profile.
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Pre-clinical safety
We assessed the safety of SIS-ECM applied to the epicardial surface after MI using a pre-clinical animal model by examining myocardial fibrosis, intrathoracic adhesion formation, and LV compliance. We show EIR does not increase myocardial fibrosis, despite the addition of exogenous ECM. We further demonstrate that postoperative adhesions are reduced in animals receiving EIR compared with animals receiving sham treatment, suggesting that SIS-ECM limits post-operative scar formation. This reduced scar formation may reduce the surgical difficulty associated with sternal re-entry. Although other groups observed immune or fibrotic reactions in response to the implantation of SIS-ECM in an intracardiac circumstance in children, 12 we show that SIS-ECM implanted onto the epicardial surface of the heart does not elicit a fibrotic response, suggesting that effects of SIS-ECM may depend on the location of implantation or the age of the recipient.
LV compliance was assessed by ex vivo passive pressure distention, the gold standard for assessment of global LV stiffness, 29 to ensure that the addition of non-compliant SIS-ECM biomaterial did not impede LV filling. EIR did not adversely alter global LV compliance and therefore should not negatively impact LV filling. We also measured myocardial strain by CMR to assess the regional effects of SIS-ECM on myocardial restraint. Morita et al 23 previously correlated changes in longitudinal strain patterns in the anterior wall after MI with response to other infarct-limiting therapies. We measured peak systolic longitudinal strain referenced to the end-diastolic epicardial surface. Negative strain reflects shortening of the LV myocardium during systole, which is expected to occur in healthy functional myocardium. Positive strain reflects lengthening of the LV myocardium indicating dyskinesis. We observed a trend toward dyskinesis in animals receiving sham treatment; however, in animals receiving EIR, a neutral strain was observed at baseline, indicating that the SIS-ECM biomaterial may be restraining paradoxical myocardial tissue deformation, preventing dyskinesis. Together, these data demonstrate that EIR limits dyskinesis without adversely altering LV compliance.
EIR enhances functional myocardial recovery after MI
In a rodent model of MI, we previously demonstrated that EIR attenuates LV dilation and improves LV contractility, resulting in a clinically significant increase in ejection fraction. 8 Given the small size of the rodent heart, this model lacked the spatial resolution to determine whether EIR positively influences global LV function by promoting recovery of the infarcted myocardium or enhancing compensation by the remote myocardium. In this study, we adapted a larger pre-clinical porcine model to examine the regional effects of EIR on the infarct, peri-infarct, and remote myocardial territories. Ischemia-reperfusion of the diagonal coronary arteries produced a discrete MI ideal for regional analysis. Global LV function was not significantly affected; however, an improvement in regional wall thickening was observed in animals that received EIR, demonstrating that EIR improves contractility by promoting functional recovery of the infarcted myocardium.
We also show that EIR promotes functional recovery of the infarcted myocardium beyond that achieved by reperfusion alone. Kim et al 25 previously showed that after MI, o10% of myocardial segments with 450% LGE by CMR demonstrate functional improvement in response to complete revascularization, establishing 450% LGE as the threshold for predicting myocardial viability for surgical revascularization. Similarly, in our ischemia-reperfusion model, we observed no significant improvement in function within the infarcted myocardium of animals receiving sham treatment. However, a significant improvement in myocardial function was observed within the infarcted myocardium of animals receiving EIR. This improvement demonstrates that EIR promotes functional recovery of the infarcted myocardium previously thought to be non-viable when treated by conventional revascularization alone.
Putative mechanisms of benefit
Infarct size was neither variable between groups nor significantly altered over time in either group, suggesting that the functional recovery observed was unrelated to infarct size. Significant changes in markers of improved myocardial healing were observed, including epicardial activation and vasculogenesis. Epicardial thickening in response to ischemic injury has been shown to act as a source of paracrine factors, including the angiogenic factors fibroblast growth factor-2 and vascular endothelial growth factor, which condition the underlying myocardium for repair. 18 Epicardial thickening was enhanced by EIR. Furthermore, numerous key stem cell niches are located within the epicardium. 19, 20 Activation and mobilization of these stem cell populations through EMT is believed to occur in response to ischemic injury and acts to stimulate myocardial repair ( Figure 5) . 21, 22, 30 Following EMT, these cells can differentiate into vascular smooth muscle cells and form new blood vessels (vasculogenesis) within the infarcted myocardium. 31, 32 We show that EIR results in increased vascularity, particularly small arteriolar networks closely associated with islands of intact cardiomyocytes, within the infarcted myocardium ( Figure 4A ), suggesting that EIR may restore perfusion at a microvascular level to rescue otherwise hibernating myocardium. Recovery of function in this hibernating but intact myocardium may explain the improvement in function observed in the absence of altered infarct size, although further investigation of this putative mechanism is required.
Clinical perspective
A significant subset of patients admitted to the hospital for acute coronary syndromes undergo surgical revascularization early after MI. 33 These patients are at increased risk of incomplete revascularization, and the infarcted myocardium is not directly addressed at the time of CABG. These preclinical data suggest that when applied in addition to successful reperfusion, EIR may promote functional recovery in what was previously deemed non-viable myocardium. 
Limitations
Although we have yet to identify the optimal therapeutic window for EIR after MI, we hypothesize that the greatest benefits will be achieved early. We appreciate that our preclinical model is likely to portray the maximal benefits of EIR, as it was applied immediately after ischemic injury. Clinically, if performed as an adjunct to CABG, most patients will receive EIR during the sub-acute stage after MI. We previously demonstrated that EIR improves myocardial function when applied during the sub-acute to chronic stage after MI. 8 Although the optimal therapeutic window is currently under investigation, our findings suggest that patients undergoing CABG during the acute or sub-acute stages after MI may stand to benefit from adjunct EIR. However, given the small sample size of this study, further pre-clinical studies may be warranted before clinical translation.
In conclusion, EIR is safe and effective. EIR restores regional myocardial function beyond that which can be achieved by reperfusion alone.
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